Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Renée Else MichelsMaria de FransescoKoshu MahajanGerald J D HengstmanKrijn M H SchiffersSangeeta BudhiaGerard HartyMarieke Krol

Published in: Applied health economics and health policy (2020)

The base-case analysis shows that treatment of RRMS with cladribine tablets is cost effective versus alemtuzumab and fingolimod in HDA patients, and cost effective versus natalizumab in RES patients, at a threshold of €50,000. Driven by the lower costs, cladribine tablets were cost effective (dominant) in all base-case analyses. However, given that outcomes are based on indirect comparisons and post hoc subgroup analysis, as well as the uncertainty surrounding the outcomes, the results presented in this paper should be interpreted with caution.

Keyphrases

multiple sclerosis
white matter
end stage renal disease
newly diagnosed
chronic kidney disease
randomized controlled trial
type diabetes
clinical trial
systemic lupus erythematosus
peritoneal dialysis
patient reported outcomes
study protocol
disease activity